Chicago, ILNCT05042258Now EnrollingIRB Ready

Atopic Dermatitis Clinical Trial in Chicago, IL

Access cutting-edge atopic dermatitis treatment through this phase 4 clinical trial at a research site in Chicago. Study-provided care at no cost to qualified participants.

Sponsored by Northwestern University

Quick Self-Assessment

See if you qualify for this Chicago location

Preparing your pre-screening questions…

Expert Care in Chicago

Access atopic dermatitis specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related atopic dermatitis treatment provided free

Apply for This Chicago Location

Check if you qualify for this atopic dermatitis clinical trial in Chicago, IL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Chicago

    Convenient for IL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Chicago site if eligible
  4. 4Begin participation

About This Atopic Dermatitis Study in Chicago

Single center, prospective, Open label study of sleep, pruritus and circadian function pre/post 12-weeks of dupilumab treatment in children 6-17 years old

Sponsor: Northwestern University

Who Can Participate

Inclusion Criteria

Participants, 6-17 years old at time of enrollment.
Moderate to severe chronic AD inadequately controlled by topical treatment, diagnosed according to Hanifin and Rajka criteria by a pediatric dermatologist or allergist.
AD severity will be determined at baseline with Validated Investigator Global Assessment (vIGA) score of moderate (3) or severe (4).
Patient assessed or parent-proxy (under 8 years old) PROMIS sleep disturbance T-score ≥60.
Willing and able to comply with visits and study-related procedures.
On stable regimens (consistent use 14 days before Day 1 of study enrollment) of inhaled corticosteroids, topical steroids, and antihistamines.

Exclusion Criteria

Poorly controlled asthma (Asthma Control Test ≤19).
Self-reported sleep disturbance on 2 or more nights in the past 7 days due to allergic rhinitis.
Use of concomitant medication that causes scratching.
Major medical condition (such as cancer).
Active condition that could affect sleep, such as obstructive sleep apnea, restless leg syndrome, insomnia, narcolepsy, severe sleep disordered breathing, severe depression, COVID-19, or hives (urticaria).
Having applied topical steroids within 7 days of first or second PSG (important for biomarkers assessment).
Use of systemic immunosuppressant within 30 days of first PSG.
Having showered or used moisturizers within 12 hours of first or second PSG.
Unable to communicate in English (some PROMIS questionnaires not available in translation).
Other contraindication to receiving dupilumab (such as history of allergic reaction to dupilumab or any of its components).
Clinical blindness (circadian disturbing).

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Chicago?

Yes, this clinical trial (NCT05042258) has an active research site in Chicago, IL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Atopic Dermatitis Treatment Options in Chicago, IL

If you're searching for atopic dermatitis treatment options in Chicago, IL, this clinical trial (NCT05042258) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Chicago research site is actively enrolling participants for this phase 4 clinical trial. You'll receive care from experienced atopic dermatitis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all atopic dermatitis clinical trials near you to find additional studies recruiting in your area.

More Atopic Dermatitis Trials in Chicago, IL

See all atopic dermatitis clinical trials recruiting in Chicago — not just this study.

Browse Atopic Dermatitis Trials in Chicago →

Browse More Trials by Condition

Atopic Dermatitis TrialsInterstitial Cystitis TrialsAll Conditions →

Ready to Join in Chicago?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Chicago, IL